Literature DB >> 15609303

Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis.

Qi Chen1, Rihui Chao, Hongsheng Chen, Xuerui Hou, Huifang Yan, Shufeng Zhou, Wenlie Peng, Anlong Xu.   

Abstract

Beta-carboline alkaloids such as harmine are present in medicinal plants such as Peganum harmala that have been used as folk medicine in anticancer therapy. In our study, 9 harmine derivatives (including harmine) were investigated for their antitumor effects and acute toxicities in mice, and the structure-activity relationship (SAR) was also analyzed. Administration of these compounds resulted in tumor inhibition rates of 15.3-49.5% in mice bearing Lewis Lung Cancer, sarcoma180 or HepA tumor, with the highest value of 49.5% from compound 6. Acute toxicity studies showed that all these compounds except compounds 2 and 5 caused remarkable acute neurotoxicities manifested by tremble, twitch and jumping. SAR analysis indicated that the formate substitution at R3 of the tricyclic skeleton reduced their neurotoxicity, while the short alkyl or aryl substitution at R9 increased the antitumor activity. The harmine and its derivatives resulted in in vitro cytotoxicity (IC50) values of 0.011-0.021 micromol/ml in HepG2 cells, with compound 8 being the most potent among all agents tested. Compounds 1, 6, 7 and 8 induced apoptosis in HepG2 cells, with the highest apoptotic rate (55.34%) from compound 6. Western blotting analysis demonstrated that compound 6 completely inhibited the expression of Bcl-2 gene, and compounds 1 and 8 produced a significant inhibition by 40 and 60%, respectively, compared to the control, while compound 7 did not alter the level of Bcl-2. Compounds 1, 6, 7 and 8 upregulated the expression of death receptor Fas by approximately 50-120%. All these findings indicate that compounds with both substitutions at R3 and R9 (such as compound 5) have high antitumor activity and low toxicity, which might be chosen as lead molecules for further development. Further studies on the effects of harmine derivatives on key regulators for tumor cell apoptosis are needed. 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15609303     DOI: 10.1002/ijc.20703

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

1.  Harmine hydrochloride inhibits Akt phosphorylation and depletes the pool of cancer stem-like cells of glioblastoma.

Authors:  Huailei Liu; Dayong Han; Yaohua Liu; Xu Hou; Jianing Wu; Huadong Li; Jie Yang; Chen Shen; Guang Yang; Changyu Fu; Xianfeng Li; Hui Che; Jing Ai; Shiguang Zhao
Journal:  J Neurooncol       Date:  2013-02-08       Impact factor: 4.130

2.  Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.

Authors:  Kunal Kumar; Peng Wang; Roberto Sanchez; Ethan A Swartz; Andrew F Stewart; Robert J DeVita
Journal:  J Med Chem       Date:  2018-08-21       Impact factor: 7.446

Review 3.  Natural Bioactive Compounds Targeting Epigenetic Pathways in Cancer: A Review on Alkaloids, Terpenoids, Quinones, and Isothiocyanates.

Authors:  Nasreddine El Omari; Saad Bakrim; Mohamed Bakha; José M Lorenzo; Maksim Rebezov; Mohammad Ali Shariati; Sara Aboulaghras; Abdelaali Balahbib; Mars Khayrullin; Abdelhakim Bouyahya
Journal:  Nutrients       Date:  2021-10-22       Impact factor: 5.717

4.  Alkaloids from the seeds of Peganum harmala showing antiplasmodial and vasorelaxant activities.

Authors:  Adil Astulla; Kazumasa Zaima; Yosuke Matsuno; Yusuke Hirasawa; Wiwied Ekasari; Aty Widyawaruyanti; Noor Cholies Zaini; Hiroshi Morita
Journal:  J Nat Med       Date:  2008-06-04       Impact factor: 2.343

5.  Harmine, a Novel DNA Methyltransferase 1 Inhibitor in the Leukemia Cell Line.

Authors:  Arezoo Oodi; Hamed Norouzi; Naser Amirizadeh; Mahin Nikougoftar; Zahra Vafaie
Journal:  Indian J Hematol Blood Transfus       Date:  2017-01-17       Impact factor: 0.900

6.  High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer.

Authors:  Kirsi Ketola; Miro Viitala; Pekka Kohonen; Vidal Fey; Zoran Culig; Olli Kallioniemi; Kristiina Iljin
Journal:  J Mol Biochem       Date:  2016-03-30

7.  Harmine activates intrinsic and extrinsic pathways of apoptosis in B16F-10 melanoma.

Authors:  Thayele Purayil Hamsa; Girija Kuttan
Journal:  Chin Med       Date:  2011-03-23       Impact factor: 5.455

8.  Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.

Authors:  Michael Tarpley; Helen O Oladapo; Dillon Strepay; Thomas B Caligan; Lhoucine Chdid; Hassan Shehata; Jose R Roques; Rhashad Thomas; Christopher P Laudeman; Rob U Onyenwoke; David B Darr; Kevin P Williams
Journal:  Eur J Pharm Sci       Date:  2021-03-27       Impact factor: 5.112

9.  A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer.

Authors:  Zachary A Yochum; Jessica Cades; Lucia Mazzacurati; Neil M Neumann; Susheel K Khetarpal; Suman Chatterjee; Hailun Wang; Myriam A Attar; Eric H-B Huang; Sarah N Chatley; Katriana Nugent; Ashwin Somasundaram; Johnathan A Engh; Andrew J Ewald; Yoon-Jae Cho; Charles M Rudin; Phuoc T Tran; Timothy F Burns
Journal:  Mol Cancer Res       Date:  2017-08-29       Impact factor: 5.852

10.  Application of the central composite design to optimize the preparation of novel micelles of harmine.

Authors:  Yong-Yan Bei; Xiao-Feng Zhou; Ben-Gang You; Zhi-Qiang Yuan; Wei-Liang Chen; Peng Xia; Yang Liu; Yong Jin; Xiao-Juan Hu; Qiao-Ling Zhu; Chun-Ge Zhang; Xue-Nong Zhang; Liang Zhang
Journal:  Int J Nanomedicine       Date:  2013-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.